China SXT Pharmaceuticals (SXTC) Change in Account Payables: 2018-2025
- China SXT Pharmaceuticals' Change in Account Payables rose 11.76% to -$1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$71,329, marking a year-over-year decrease of 355.56%. This contributed to the annual value of -$114,081 for FY2025, which is 289.97% down from last year.
- Latest data reveals that China SXT Pharmaceuticals reported Change in Account Payables of -$1.2 million as of Q3 2025, which was down 201.54% from $1.2 million recorded in Q1 2025.
- In the past 5 years, China SXT Pharmaceuticals' Change in Account Payables registered a high of $1.5 million during Q1 2022, and its lowest value of -$1.5 million during Q3 2021.
- Its 3-year average for Change in Account Payables is $1,670, with a median of -$8,946 in 2025.
- Within the past 5 years, the most significant YoY rise in China SXT Pharmaceuticals' Change in Account Payables was 26.11% (2021), while the steepest drop was 24.97% (2021).
- Quarterly analysis of 5 years shows China SXT Pharmaceuticals' Change in Account Payables stood at -$1.5 million in 2021, then grew by 11.73% to -$1.3 million in 2022, then rose by 0.82% to -$1.3 million in 2023, then fell by 2.81% to -$1.3 million in 2024, then increased by 11.76% to -$1.2 million in 2025.
- Its Change in Account Payables stands at -$1.2 million for Q3 2025, versus $1.2 million for Q1 2025 and -$1.3 million for Q3 2024.
